Corbion (CRBN) CMD 2025 summary

Strategic direction and transformation

• Launched BRIGHT 2030 strategy to lead in sustainable specialty food ingredients, focusing on natural preservation, nutrition, and clean-label solutions, with streamlined operations and divestment of non-core businesses.

• Achieved Advance 2025 targets, including margin expansion from 13% to 16%, 10 consecutive quarters of positive free cash flow, and strengthened the balance sheet.

• Strategic ownership review of the PLA portfolio and defocus on non-food lactic acid applications to prioritize core food and nutrition segments.

• Continued investment in innovation, with €90m allocated, over 2,400 patents/applications, and more than 700 customer projects annually.

• Selective bolt-on M&A in natural preservation and food solutions to access higher-growth markets.

Market trends and growth opportunities

• Consumer demand is shifting toward natural, clean-label ingredients, with regulatory and market trends accelerating the move away from artificial additives.

• Natural preservation and nutrition markets are growing, with addressable markets expanding at 2-6% CAGR through 2030.

• The company holds a 25% share in the natural food preservation market and is expanding into LATAM and APAC.

• Biomedical Polymers and Nutrition (omega-3 oils) are targeted for double-digit growth, leveraging fermentation technology and strategic partnerships.

• Sustainability is embedded, with 98% renewable raw materials, 99% deforestation-free, and net-zero emissions targeted by 2050.

Financial performance and guidance

• Sales grew at a 9% CAGR and adjusted EBITDA at 8% CAGR from 2020-2025, with margin expansion driven by pricing, efficiency, and cost reduction.

• Medium-term (2026-2028) targets: organic sales growth 3-6% p.a., adjusted EBITDA margin ~18%, cumulative free cash flow ~€270m, ROCE ~13%, and double-digit EPS growth.

• Capex of €255 million planned for 2026-2028, with investments focused on food preservation, nutrition, and biomedical polymers.

• Net debt/EBITDA targeted at 1.5-2.5x, with working capital stable at ~24% of sales.